Skip to main content

Peer Review reports

From: A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China

Original Submission
11 Oct 2023 Submitted Original manuscript
2 Nov 2023 Reviewed Reviewer Report
6 Nov 2023 Reviewed Reviewer Report
14 Nov 2023 Reviewed Reviewer Report
20 Nov 2023 Reviewed Reviewer Report - Zoya Kuzmina
29 Jan 2024 Author responded Author comments - Ying Wang
Resubmission - Version 2
29 Jan 2024 Submitted Manuscript version 2
4 Feb 2024 Reviewed Reviewer Report
12 Feb 2024 Reviewed Reviewer Report
13 Feb 2024 Reviewed Reviewer Report - Zoya Kuzmina
1 Mar 2024 Author responded Author comments - Ying Wang
Resubmission - Version 3
1 Mar 2024 Submitted Manuscript version 3
6 Mar 2024 Author responded Author comments - Ying Wang
Resubmission - Version 4
6 Mar 2024 Submitted Manuscript version 4
Publishing
11 Mar 2024 Editorially accepted
26 Mar 2024 Article published 10.1186/s12916-024-03348-5

You can find further information about peer review here.

Back to article page